Zydus life science has announced the completion of its postal ballot voting process for a special resolution, with results declared on December 12, 2025. The pharmaceutical company submitted detailed voting results to both BSE Limited and National Stock Exchange of India Limited, fulfilling its regulatory obligations under the SEBI Listing Regulations.

Postal Ballot Process Details

The company facilitated remote e-voting through Central Depository Services (India) Limited platform for its shareholders. The voting process was structured with specific timelines to ensure maximum participation from eligible shareholders.

Voting Results by Category

The postal ballot results show participation across different shareholder categories, with detailed breakdowns of votes polled and voting patterns. The promoter and promoter group category recorded significant participation in the voting process.

Regulatory Compliance

The company has fulfilled its obligations under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed voting results have been submitted along with the Scrutinizer's Report on remote e-voting to ensure transparency and compliance.

The voting results and related documents are being uploaded on the company's official website for public access. This postal ballot process was conducted without a physical Annual General Meeting, as indicated by the "Not Applicable" status for AGM-related parameters in the official documentation.

Corporate Communication

Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), signed the official communication to the stock exchanges. The company maintains its registered office at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), near Vaishnodevi Circle, S.G. Highway, Ahmedabad-382481, Gujarat.

Zydus Lifesciences has announced a strategic exclusive partnership with Formycon for the licensing and supply of a biosimilar to Keytruda in the United States and Canada markets. This collaboration marks a significant development in the pharmaceutical company's biosimilar portfolio expansion strategy.

Partnership Details

The exclusive partnership between Zydus Lifesciences and Formycon focuses specifically on the North American markets, covering both the United States and Canada. The agreement encompasses licensing rights and supply arrangements for the biosimilar version of Keytruda, a widely prescribed cancer treatment.

Strategic Significance

This partnership represents a strategic move for Zydus Lifesciences to strengthen its position in the competitive biosimilar market. The collaboration with Formycon provides the company with access to advanced biosimilar technology and manufacturing capabilities for one of the most significant oncology treatments in the pharmaceutical industry.

The exclusive nature of the partnership ensures that Zydus Lifesciences will have dedicated access to Formycon's biosimilar Keytruda for the specified North American markets. This arrangement positions the company to capitalize on the growing demand for cost-effective biosimilar alternatives in the oncology segment.

Market Implications

The partnership focuses on two of the largest pharmaceutical markets globally, with the United States and Canada representing substantial opportunities for biosimilar penetration. The collaboration enables Zydus Lifesciences to leverage Formycon's expertise while expanding its geographic reach in the biosimilar space.

This strategic alliance demonstrates Zydus Lifesciences' commitment to building a robust biosimilar portfolio through strategic partnerships and collaborations with established biotechnology companies.